What is Thymosin Alpha-1

Thymosin Alpha-1 is a synthetic version of an endogenous 28-amino-acid peptide produced by the thymus gland, studied in research for its specific and highly potent ability to augment T-cell function. It is intended exclusively for research use.

Regarding its chemical identity, Thymosin has a molecular formula of C129H215N33O55 and a molecular weight of 3108.3 g/mol. Its reported canonical sequence is Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn. A confirmed CAS number is not available in open primary reference sources and is therefore omitted.

Its synonyms include Thymosin.

Product for research use.

Mechanism of action of Thymosin

Thymosin Alpha-1 binds to Toll-like receptors on dendritic cells and directly influences T-cell maturation. It enhances the production of Th1 cytokines (like IL-2 and IFN-gamma), which are crucial for fighting viral infections and activating cytotoxic T-cells against abnormal cells.

Pharmacokinetics and pharmacodynamics of Thymosin

When administered systemically, it has a plasma half-life of approximately 2 hours. It does not stay in the system long but triggers a sustained immune response that persists for days following administration.

Scientific evidence on Thymosin

The available evidence on Thymosin is preliminary and largely inconclusive, and should be interpreted with caution. The literature describes it as having been investigated for multiple indications in preclinical models.

Widely studied and clinically approved in over 30 countries (as Zadaxin) for the treatment of Hepatitis B and C, and as an immune enhancer for vaccines and chemotherapy. Preclinical evidence strongly supports its efficacy in reversing immune exhaustion.

Thymosin applications in research

Ideal for (research context):
– In vitro and preclinical studies of its specific receptor pathways.
– Investigation of tissue repair, cell proliferation, and functional restoration in laboratory models.
– Comparative work with related peptides.

Not applicable for:
– clinical, diagnostic or therapeutic use.
– Any administration to humans or animals outside of an authorized research protocol.

Product for research use.

Thymosin protocols in preclinical studies

The literature consulted does not include numerical doses from studies that can be cited for Thymosin, so no trial schemes or quantities are specified.

The presentations of this product (Various (e.g., 5MG)) refer only to the amount of lyophilized peptide per vial (or volume for liquids) and do not constitute a dosage recommendation. The design of any protocol, including concentrations and working volumes, is the responsibility of the researcher, based on their experimental objectives and the relevant primary literature.

Information provided exclusively for research purposes.

Reconstitution and manipulation of Thymosin

As a general guideline for laboratory handling, lyophilized peptides such as Thymosin are usually reconstituted with bacteriostatic water (sterile water with approximately 0.9% benzyl alcohol).

Add the solvent slowly down the side of the vial, letting it run over the lyophilized powder; avoid injecting the stream directly onto the powder.
Do not shake: gently rotate the vial until completely dissolved.
Adjust the solvent volume according to the desired working concentration, considering the Various (e.g., 5MG) contents of the vial.

These guidelines are for general technique and do not replace the internal procedures of each laboratory.

Thymosin Stability and Storage

As a standard laboratory handling procedure for peptides:

Freeze-dried (unreconstituted): This is the most stable form. It is best preserved by freezing and protecting it from moisture and light for long-term storage.
Reconstituted: once in solution, the peptide is less stable and must be kept refrigerated, being used within a short period; for extended storage, freezing in aliquots is usually preferred.
Avoid repeated freeze-thaw cycles, as they can degrade the peptide.

Given that the molecule is characterized by rapid enzymatic degradation in biological media, careful cold chain management is especially relevant.

Documented Thymosin security profile

The documented safety information in open sources for Thymosin is limited and should be interpreted with caution, also considering that it is research material and not for clinical use.

Considered to have an excellent safety profile. Because it modulates rather than forcefully overrides the immune system, it rarely causes the severe “cytokine storms” associated with more aggressive immunotherapies. Tolerance is generally extremely high.

Formal contraindications and adverse event rates are not available in the consulted literature, so no figures are reported.

Thymosin in a comparative context

Compared to Thymalin (a multi-peptide extract), Thymosin Alpha-1 is a highly purified, single synthetic molecule targeting a specific pathway (Th1 cytokine release). Compared to LL-37, TA-1 does not kill pathogens directly; it arms the immune system to do it.

History and development of Thymosin

Isolated in 1972 by Allan Goldstein from fraction 5 of thymus extracts. It became the most successful and widely recognized thymic peptide in Western medicine, extensively utilized in virology and oncology research.